Prestige Consumer Healthcare Inc. $PBH Stake Lifted by Leeward Investments LLC MA

Key Points

• Leeward Investments increased its Prestige Consumer Healthcare stake by 20.3% in the third quarter, acquiring 88,693 shares and bringing its holdings to 526,609 shares worth approximately $24.2 million.
• Institutional ownership remains very high at 99.95%, with several other investment firms also adding to or initiating positions in PBH during the quarter.
• PBH has a mixed analyst outlook, with an average rating of “Hold” and a consensus price target of $67.67. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.98 EPS and $265.71 million in revenue.

Leeward Investments LLC MA grew its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 20.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 526,609 shares of the company's stock after buying an additional 88,693 shares during the period. Prestige Consumer Healthcare accounts for 1.2% of Leeward Investments LLC MA's investment portfolio, making the stock its 16th largest holding. Leeward Investments LLC MA owned about 1.11% of Prestige Consumer Healthcare worth $24,156,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the stock. Evergreen Capital Management LLC acquired a new position in Prestige Consumer Healthcare in the third quarter valued at $243,000. Pinnacle Associates Ltd. increased its position in shares of Prestige Consumer Healthcare by 2.9% during the third quarter. Pinnacle Associates Ltd. now owns 24,646 shares of the company's stock worth $1,131,000 after purchasing an additional 689 shares in the last quarter. Milestone Asset Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter worth about $1,251,000. GAMMA Investing LLC lifted its holdings in shares of Prestige Consumer Healthcare by 22.5% in the 3rd quarter. GAMMA Investing LLC now owns 3,219 shares of the company's stock valued at $148,000 after purchasing an additional 591 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Prestige Consumer Healthcare by 2,152.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,117 shares of the company's stock valued at $326,000 after purchasing an additional 6,801 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PBH. Zacks Research upgraded Prestige Consumer Healthcare from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 30th. Weiss Ratings restated a "sell (d+)" rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of "Hold" and a consensus target price of $67.67.

Prestige Consumer Healthcare Trading Down 0.0%

NYSE PBH opened at $47.78 on Monday. The firm's fifty day moving average is $48.81 and its two-hundred day moving average is $50.09. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $71.07. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The firm has a market cap of $2.26 billion, a PE ratio of 13.38, a P/E/G ratio of 1.50 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The company had revenue of $265.71 million for the quarter, compared to analysts' expectations of $253.02 million. During the same period in the previous year, the company posted $0.90 EPS. Prestige Consumer Healthcare's revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Analysts expect that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc NYSE: PBH is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company's brands include Dramamine and Bonine for motion-sickness relief; BC and Goody's for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer's Eve for feminine care.

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.